Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 187

1.

Effects of rivastigmine on cognitive function in patients with traumatic brain injury.

Silver JM, Koumaras B, Chen M, Mirski D, Potkin SG, Reyes P, Warden D, Harvey PD, Arciniegas D, Katz DI, Gunay I.

Neurology. 2006 Sep 12;67(5):748-55.

PMID:
16966534
2.

Long-term effects of rivastigmine capsules in patients with traumatic brain injury.

Silver JM, Koumaras B, Meng X, Potkin SG, Reyes PF, Harvey PD, Katz DI, Gunay I, Arciniegas DB.

Brain Inj. 2009 Feb;23(2):123-32. doi: 10.1080/02699050802649696.

PMID:
19191091
3.

Rivastigmine for cognitive impairment after spontaneous subarachnoid haemorrhage: a pilot study.

Wong GK, Wong R, Mok V, Wong A, Fan D, Leung G, Chan A, Poon WS.

J Clin Pharm Ther. 2009 Dec;34(6):657-63. doi: 10.1111/j.1365-2710.2009.01056.x.

PMID:
20175798
5.

Effects of rivastigmine on memory and cognition in multiple sclerosis.

Shaygannejad V, Janghorbani M, Ashtari F, Zanjani HA, Zakizade N.

Can J Neurol Sci. 2008 Sep;35(4):476-81.

PMID:
18973065
6.

Rivastigmine treatment as an add-on to antipsychotics in patients with schizophrenia and cognitive deficits.

Chouinard S, Stip E, Poulin J, Melun JP, Godbout R, Guillem F, Cohen H.

Curr Med Res Opin. 2007 Mar;23(3):575-83.

PMID:
17355738
7.

Neural correlates of adjunctive rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind fMRI study.

Kumari V, Aasen I, ffytche D, Williams SC, Sharma T.

Neuroimage. 2006 Jan 15;29(2):545-56. Epub 2005 Sep 21.

PMID:
16181792
8.

A randomized controlled trial of rivastigmine in patients with cognitive impairment no dementia because of cerebrovascular disease.

Narasimhalu K, Effendy S, Sim CH, Lee JM, Chen I, Hia SB, Xue HL, Corrales MP, Chang HM, Wong MC, Chen CP, Tan EK.

Acta Neurol Scand. 2010 Apr;121(4):217-24. doi: 10.1111/j.1600-0404.2009.01263.x. Epub 2009 Sep 26.

PMID:
19951274
9.

Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study.

Ballard C, Sauter M, Scheltens P, He Y, Barkhof F, van Straaten EC, van der Flier WM, Hsu C, Wu S, Lane R.

Curr Med Res Opin. 2008 Sep;24(9):2561-74. doi: 10.1185/03007990802328142 . Epub 2008 Jul 31.

PMID:
18674411
10.

Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease.

Burn D, Emre M, McKeith I, De Deyn PP, Aarsland D, Hsu C, Lane R.

Mov Disord. 2006 Nov;21(11):1899-907.

PMID:
16960863
11.

Effects of rivastigmine on cognitive function in patients with traumatic brain injury.

Noble JM, Hauser WA.

Neurology. 2007 May 15;68(20):1749; author reply 1750. No abstract available.

PMID:
17502565
12.

Identification of responders and reactive domains to rivastigmine in Alzheimer's disease.

Frankfort SV, Appels BA, de Boer A, Tulner LR, van Campen JP, Koks CH, Beijnen JH, Schmand BA.

Pharmacoepidemiol Drug Saf. 2007 May;16(5):545-51.

PMID:
17109476
13.

Rivastigmine for HIV-associated neurocognitive disorders: a randomized crossover pilot study.

Simioni S, Cavassini M, Annoni JM, Métral M, Iglesias K, Rimbault Abraham A, Jilek S, Calmy A, Müller H, Fayet-Mello A, Giacobini E, Hirschel B, Du Pasquier RA.

Neurology. 2013 Feb 5;80(6):553-60. doi: 10.1212/WNL.0b013e3182815497. Epub 2013 Jan 23.

PMID:
23345635
14.

A pilot study evaluating the efficacy and safety of rivastigmine in patients with mixed dementia.

Potkin SG, Alva G, Gunay I, Koumaras B, Chen M, Mirski D.

Drugs Aging. 2006;23(3):241-9.

PMID:
16608379
15.

The effects of rivastigmine on processing speed and brain activation in patients with multiple sclerosis and subjective cognitive fatigue.

Huolman S, Hämäläinen P, Vorobyev V, Ruutiainen J, Parkkola R, Laine T, Hämäläinen H.

Mult Scler. 2011 Nov;17(11):1351-61. doi: 10.1177/1352458511412061. Epub 2011 Aug 16.

PMID:
21846692
16.

Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study.

Poewe W, Wolters E, Emre M, Onofrj M, Hsu C, Tekin S, Lane R; EXPRESS Investigators.

Mov Disord. 2006 Apr;21(4):456-61.

PMID:
16229010
18.

A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease--rivastigmine patch versus capsule.

Winblad B, Cummings J, Andreasen N, Grossberg G, Onofrj M, Sadowsky C, Zechner S, Nagel J, Lane R.

Int J Geriatr Psychiatry. 2007 May;22(5):456-67.

PMID:
17380489
19.

Rivastigmine versus placebo in hyperhomocysteinemic Parkinson's disease dementia patients.

Barone P, Burn DJ, van Laar T, Hsu C, Poewe W, Lane RM.

Mov Disord. 2008 Aug 15;23(11):1532-40. doi: 10.1002/mds.21997.

PMID:
18581467
20.

IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease.

Winblad B, Grossberg G, Frölich L, Farlow M, Zechner S, Nagel J, Lane R.

Neurology. 2007 Jul 24;69(4 Suppl 1):S14-22.

PMID:
17646619

Supplemental Content

Support Center